The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats

The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats

Abstract Background Sodium glucose co-transporter 2 inhibitor (SGLT2i), a new class of anti-diabetic drugs acting on inhibiting glucose resorption by kidneys, is shown beneficial in reduction of heart failure hospitalization and cardiovascular mortality. The mechanisms remain unclear. We hypothesize...

Full description

Bibliographic Details
Main Authors: Hsiang-Chun Lee, Yi-Lin Shiou, Shih-Jie Jhuo, Chia-Yuan Chang, Po-Len Liu, Wun-Jyun Jhuang, Zen-Kong Dai, Wei-Yu Chen, Yun-Fang Chen, An-Sheng Lee
Format: Article
Language:English
Published: BMC 2019-04-01
Series:Cardiovascular Diabetology
Subjects:
SGLT2 inhibitor
Empagliflozin
Hypertensive
Heart failure
Cardiac fibrosis
Hemodynamics
Online Access:http://link.springer.com/article/10.1186/s12933-019-0849-6

Internet

http://link.springer.com/article/10.1186/s12933-019-0849-6

Similar Items